MoonLake reports all endpoints met in phase 3 trial of sonelokimab for psoriatic arthritis

MoonLake Immunotherapeutics said its lead nanobody sonelokimab achieved positive topline results in a phase 3 study of patients with psoriatic arthritis.

At week 16, 42.1% of participants reached an ACR50 response, indicating at least a 50% improvement in joint symptoms. Secondary endpoints were also met, with 66.5% achieving ACR20, 41.2% attaining minimal disease activity, and 61% of those with skin disease reaching PASI90.

The trial, identified as IZAR-1, enrolled biologic-naïve patients and used a placebo control arm; detailed comparative data remain blinded until the study is completed.

CEO Jorge Santos de Silva highlighted the simultaneous improvement across multiple clinically relevant measures as a key milestone for the company and patients.